Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes

International Journal of Cancer

Volumn 89, Issue 1, 2000, Pages 100-104

  Pfister, Christian ^a   Larue, Hélène ^a   Moore, Lynne ^a   Lacombe, Louis ^a   Veilleux, Chantal ^a   Tetu, Bernard ^a   Meyer, François ^a   Fradet, Yves ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UROTHELIUM;

AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0034688223     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000120)89:1<100::AID-IJC16>3.0.CO;2-Q     Document Type: Article

References (27)

1. ALLARD, P., FRADET, Y., TETU, B., BERNARD, P. and THE QUEBEC UROLOGY RESEARCH GROUP, Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin. Cancer Res., 1, 1195-1202 (1995).
2. CORDON-CARDO, C., Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Amer. J. Pathol., 147, 545-560 (1995).
3. CORDON-CARDO, C., DALBAGNI, G., SAEZ, G.T., OLIVA, M.R., ZHANG, Z.F., ROSAI, J., REUTER, V.E. and PELLICIER, A., p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer, 56, 347-353 (1994).
4. 1 checkpoint control. Cell, 82, 675-684 (1995).
5. EL-DEIRY, W.S., TOKINO, T., VELCULESCU, V.E., LEVY, D.B., PARSONS, R., TRENT, J.M., LIN, D., MERCER, W.E., KINZLER, K.W. and VOGELSTEIN, B., WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
6. ESRIG, D., SPRUCK, C.H., NICHOLS, P.W., CHAIWUN, B., STEVEN, K., GROSHEN, S., CHEN, S.C., SKINNER, D.G., JONES, P.A. and COTE, R.J., p53 nuclear accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder tumors. Amer. J. Pathol., 143, 1389-1397 (1993).
7. FERO, M.L., RIVKIN, M., TASCH, M., PORTER, P., CAROW, C.E., FIRPO, E., POLYAK, K., TSAI, L.H., BROUDY, V., PERLMUTTER, R.M., KAUSHANSKY, K. and ROBERTS, J.M., A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27 KIP1 deficient mice. Cell, 85, 733-744 (1996).
8. FREEDMAN, D.A. and LEVINE, A.J., Regulation of the p53 protein by the MDM2 oncoprotein. Thirty-eighth GHA Clowes Memorial Award Lecture. Cancer Res., 59, 1-7 (1999).
9. WAF1/CIP1 monoclonal antibodies and immunochemical analysis of p21 expression in normal human tissues. Amer. J. Pathol., 148, 825-835 (1996).
10. KIP1. Cell, 85, 721-732 (1996).
11. KO, L.J. and PRIVES, C., Review p53: puzzle and paradigm. Gene Develop., 10, 1054-1072 (1996).
12. KURTH, K.H., DENIS, L., BOUFFIOUX, C., SYLVESTER, R., DEBRUYNE, F.M.J., PAVONE-MACALUSO, M. and OOSTERLINCK, W., Factors affecting recurrence and progression in superficial bladder tumors. Europ. J. Cancer, 31, 1840-1846 (1995).
13. WAF1/CIP1 in primary bladder tumors. Oncol. Res., 8, 409-414 (1996).
14. LARUE, H., ALLARD, P., SIMONEAU, M., NORMAND, C., PFISTER, C., MOORE, L., MEYER, F., TÊTU, B. and FRADET, Y., p53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis, (1999) in press.
15. LIANES, P., ORLOW, I., ZHANG, Z.F., OLIVA, M.R., SARKIS, A.S., REUTER, V.E. and CORDON-CARDO, C., Altered patterns of MDM2 and p53 expression in human bladder cancer. J. nat. Cancer Inst., 86, 1325-1330 (1994).
16. WAF1/CIP1 in fetal and adult tissues: simultaneous analysis with Ki-67 and p53. J. Clin. Pathol., 50, 645-653 (1997).
17. MICHIELI, P., CHEDID, M., LIN, D., PIERCE, J.H., MERCER, W.E. and GIVOL, D., Induction of WAF1/CIP1 by an independent pathway. Cancer Res., 54, 3391-3395 (1994).
18. ORLOW, I., LARUE, H., OSMAN, I., LACOMBE, L., MOORE, L., RABBANI, F., MEYER, F., FRADET, Y. and CORDON-CARDO, C., Deletions of the INK4 gene in superficial bladder tumors. Amer. J. Pathol., 155, 105-113 (1999).
19. CIP1 in muscle and other terminally differentiating cells. Science, 267, 1024-1027 (1995).
20. PFISTER, C., MOORE, L., ALLARD, P., LARUE, H., LACOMBE, L., TETU, B., MEYER, F. and FRADET, Y., Predictive value of cell cycle markers p53, MDM2, p21 and Ki-67 in superficial bladder tumor recurrence. Clin. Cancer Res. (1999), in press.
21. SCHMITZ-DRÄGER, B.J., KUSHIMA, M., GOEBELL, P., JAX, T.W., GERHARZ, C.D., BÜLTEL, H., SCHULZ, W.A., EBERT, T. and ACKERMANN, R, p53 and MDM2 in the development and progression of bladder cancer. Europ. Urol., 32, 487-493 (1997).
22. SERRANO, M., LEE, H.W., CHIN, L., CORDON-CARDO, C., BEACH, D. and DE PINHO, R., Role of the INK4, a locus in tumor suppression and cell mortality. Cell, 85, 27-37 (1996).
23. SPRUCK, C.H. and 13 OTHERS, Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54, 784-788 (1994).
24. WAF1/CIP1 expression on tumor progression in bladder cancer. J. nat. Cancer Inst., 90, 1072-1079 (1998).
25. WAF1 proteins in colorectal adenocarcinomas. Anticancer Res., 17, 2571-2576 (1997).
26. - immunophenotype associated with missense p53 mutations. J. Pathol., 181, 51-61 (1997).
27. WU, X., BAYLE, J.H., OLSON, D. and LEVINE, A.J., The p53-MDM2 autoregulatory loop. Genes Develop., 7, 1126-1132 (1993).